Drug Profile
SRA 515
Alternative Names: AZD-5153; SRA-515Latest Information Update: 31 May 2023
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class Antineoplastics; Small molecules
- Mechanism of Action BRD4 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Lymphoma; Solid tumours
Most Recent Events
- 14 Apr 2023 Pharmacodynamics and adverse events data from a preclinical study in Solid tumours presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 01 Jul 2022 Sierra Oncology has been acquired by GlaxoSmithKline
- 08 Apr 2022 Pharmacodynamics data from a preclinical study in Solid tumours presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)